ProfileGDS5678 / 1424118_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 75% 76% 76% 62% 59% 67% 71% 75% 68% 75% 74% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.835974
GSM967853U87-EV human glioblastoma xenograft - Control 24.8922874
GSM967854U87-EV human glioblastoma xenograft - Control 34.9494575
GSM967855U87-EV human glioblastoma xenograft - Control 45.203676
GSM967856U87-EV human glioblastoma xenograft - Control 55.0846676
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7907362
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6312559
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0596867
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5188471
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0539675
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1587568
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9370975
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8212774
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2264577